Edgar Filing: Epizyme, Inc. - Form 4

Epizyme, Inc. Form 4 December 17, 2013 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.								OMB Number: Expires: Estimated a burden hour response	•		
(Print or Type	Responses)										
1. Name and A Copeland F	Address of Reporting Robert A	Person *	Symbol	er Name an ne, Inc. [E		r Trad		5. Relationship of I ssuer			
(Last)	(First) (Middle)	1 2	of Earliest T	-	1		(Check	all applicable)	
C/O EPIZYME, INC., 400 (Month/ TECHNOLOGY SQUARE (12/16/2				/Day/Year) /2013t				Director 10% Owner X Officer (give title Other (specify below) EVP and CSO			
				onth/Day/Year)				 D. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
	OGE, MA 02139						Ē	erson		porting	
(City)	(State)	(Zip)					_	red, Disposed of,		-	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	3. Transactic Code (Instr. 8)		(A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common				Code v	Amount	(D)	Price				
Stock, par value \$0.0001 per share	12/16/2013			M <u>(1)</u>	4,600	А	\$ 2.19	58,144	D		
Common Stock, par value \$0.0001 per share	12/16/2013			S <u>(1)</u>	4,600	D	\$ 21.2054 (2)	53,544	D		
Common Stock, par								31,483	Ι	By Wife	

value \$0.0001 per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	e Expiration I (Month/Day	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 2.19	12/16/2013		M <u>(1)</u>	4,60) (3)	10/02/2022	Common Stock	4,600	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Copeland Robert A C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			EVP and CSO				
Signatures							
/s/ Stephen Garbacz, attorney-in-fact	1	2/17/2013					
**Signature of Reporting Person		Date					

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2013.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.08 per share to \$21.395 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3) This option is fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.